p53 Antibodies in Lung Cancer Patients
Author Information
Author(s): B. Schlichtholzl, J. Tredaniel, R. Lubin, G. Zalcman, A. Hirsch, T. Soussi
Primary Institution: Unite 301 INSERM, Institut de Genetique Moleculaire, Paris, France
Hypothesis
Do p53 antibodies occur in the sera of lung cancer patients and can they serve as early markers for the disease?
Conclusion
The study found that 24% of lung cancer patients had p53 antibodies in their sera, suggesting these antibodies may be early markers of lung cancer.
Supporting Evidence
- 24% of lung cancer patients exhibited serum antibodies to p53.
- p53 antibodies were detected in various lung cancer subtypes.
- Antibodies were always present at the time of diagnosis.
Takeaway
Some people with lung cancer have special proteins in their blood that can help doctors find the cancer earlier.
Methodology
Sera were collected from lung cancer patients and analyzed for p53 antibodies using immunoprecipitation and ELISA.
Potential Biases
Potential selection bias in patient recruitment may affect the results.
Limitations
The small sample size, especially for small-cell lung carcinoma, limits the generalizability of the findings.
Participant Demographics
Patients included 9 with small-cell lung carcinoma, 18 with squamous cell carcinoma, 10 with adenocarcinoma, and 5 with large-cell carcinoma.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website